COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective

Introduction: The side effects of systemic cancer therapy and the lack of clinical data on safety and efficacy of COVID-19 vaccination in cancer patients cause uncertainty among the patients about whether to get vaccinated or not. Here, we evaluated attitude towards and effects of COVID-19 vaccinati...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Marie Forster, Rachel Wuerstlein, Alexander Koenig, Niklas Amann, Susanne Beyer, Till Kaltofen, Tom Degenhardt, Alexander Burges, Fabian Trillsch, Sven Mahner, Nadia Harbeck, Anca Chelariu-Raicu
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://doaj.org/article/c56b223aaf9545459022a504855c2e26
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:c56b223aaf9545459022a504855c2e26
record_format dspace
spelling oai:doaj.org-article:c56b223aaf9545459022a504855c2e262021-11-04T04:26:25ZCOVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective1532-308010.1016/j.breast.2021.10.012https://doaj.org/article/c56b223aaf9545459022a504855c2e262021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S0960977621009826https://doaj.org/toc/1532-3080Introduction: The side effects of systemic cancer therapy and the lack of clinical data on safety and efficacy of COVID-19 vaccination in cancer patients cause uncertainty among the patients about whether to get vaccinated or not. Here, we evaluated attitude towards and effects of COVID-19 vaccination in patients with breast and gynecological cancer undergoing systemic cancer therapy. Methods: Since March 15th, 2021, cancer patients who received one of the approved COVID-19 vaccines were routinely interviewed about immediate and late side effects. Clinical parameters such as current therapy, time interval between therapy administration and vaccination, and changes in the therapy schedule due to vaccination were documented. The collected data were analyzed de-identified as a part of routine quality assurance. Results: By July 27th, 2021, 218 patients (74.3% breast cancer patients) had received one of two COVID-19 vaccine doses, and 112 patients had received both doses: 77.5% received Conmirnaty (BioNTech/Pfizer), 16.1% Vaxzevria (Astra Zeneca) and 5.9% COVID-19 Vaccine Moderna. The COVID-19 vaccines had an acceptable safety profile with self-limiting local and systemic adverse events, which rarely lasted >48 h post vaccination. Symptoms occurred predominantly after the second dose of the vaccine and less frequently in older patients >55 years. No vaccine-related serious adverse events were reported, and only limited effects of vaccination on the therapy schedule were observed. Conclusions: Breast and gynecologic cancer patients tolerate the COVID-19 vaccination while undergoing systemic cancer therapy without any additional side effects beyond those reported in the general population.Marie ForsterRachel WuerstleinAlexander KoenigNiklas AmannSusanne BeyerTill KaltofenTom DegenhardtAlexander BurgesFabian TrillschSven MahnerNadia HarbeckAnca Chelariu-RaicuElsevierarticleCOVID-19VaccinationCancer patientsBreast cancerGynecological cancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast, Vol 60, Iss , Pp 214-222 (2021)
institution DOAJ
collection DOAJ
language EN
topic COVID-19
Vaccination
Cancer patients
Breast cancer
Gynecological cancer
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle COVID-19
Vaccination
Cancer patients
Breast cancer
Gynecological cancer
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Marie Forster
Rachel Wuerstlein
Alexander Koenig
Niklas Amann
Susanne Beyer
Till Kaltofen
Tom Degenhardt
Alexander Burges
Fabian Trillsch
Sven Mahner
Nadia Harbeck
Anca Chelariu-Raicu
COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective
description Introduction: The side effects of systemic cancer therapy and the lack of clinical data on safety and efficacy of COVID-19 vaccination in cancer patients cause uncertainty among the patients about whether to get vaccinated or not. Here, we evaluated attitude towards and effects of COVID-19 vaccination in patients with breast and gynecological cancer undergoing systemic cancer therapy. Methods: Since March 15th, 2021, cancer patients who received one of the approved COVID-19 vaccines were routinely interviewed about immediate and late side effects. Clinical parameters such as current therapy, time interval between therapy administration and vaccination, and changes in the therapy schedule due to vaccination were documented. The collected data were analyzed de-identified as a part of routine quality assurance. Results: By July 27th, 2021, 218 patients (74.3% breast cancer patients) had received one of two COVID-19 vaccine doses, and 112 patients had received both doses: 77.5% received Conmirnaty (BioNTech/Pfizer), 16.1% Vaxzevria (Astra Zeneca) and 5.9% COVID-19 Vaccine Moderna. The COVID-19 vaccines had an acceptable safety profile with self-limiting local and systemic adverse events, which rarely lasted >48 h post vaccination. Symptoms occurred predominantly after the second dose of the vaccine and less frequently in older patients >55 years. No vaccine-related serious adverse events were reported, and only limited effects of vaccination on the therapy schedule were observed. Conclusions: Breast and gynecologic cancer patients tolerate the COVID-19 vaccination while undergoing systemic cancer therapy without any additional side effects beyond those reported in the general population.
format article
author Marie Forster
Rachel Wuerstlein
Alexander Koenig
Niklas Amann
Susanne Beyer
Till Kaltofen
Tom Degenhardt
Alexander Burges
Fabian Trillsch
Sven Mahner
Nadia Harbeck
Anca Chelariu-Raicu
author_facet Marie Forster
Rachel Wuerstlein
Alexander Koenig
Niklas Amann
Susanne Beyer
Till Kaltofen
Tom Degenhardt
Alexander Burges
Fabian Trillsch
Sven Mahner
Nadia Harbeck
Anca Chelariu-Raicu
author_sort Marie Forster
title COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective
title_short COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective
title_full COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective
title_fullStr COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective
title_full_unstemmed COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective
title_sort covid-19 vaccination in patients with breast cancer and gynecological malignancies: a german perspective
publisher Elsevier
publishDate 2021
url https://doaj.org/article/c56b223aaf9545459022a504855c2e26
work_keys_str_mv AT marieforster covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective
AT rachelwuerstlein covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective
AT alexanderkoenig covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective
AT niklasamann covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective
AT susannebeyer covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective
AT tillkaltofen covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective
AT tomdegenhardt covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective
AT alexanderburges covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective
AT fabiantrillsch covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective
AT svenmahner covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective
AT nadiaharbeck covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective
AT ancachelariuraicu covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective
_version_ 1718445299967459328